23 results about "Pancreas Inflammation" patented technology

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention belongs to the field of biological medicines, and particularly relates to application of a medicine for intervening in a mitochondrial pyruvic acid carrier in preparation of a medicine for treating acute pancreatitis and a medicine composition of the medicine. The medicine for intervening in the mitochondrial pyruvic acid carrier can reduce the serum enzyme level, relieve pancreatic pathological injury, inhibit inflammatory response, inhibit calcium overload and protect the mitochondrial function, so that pancreatic acinus cell injury is relieved, the effect of treating acute pancreatitis is achieved, and the medicine has a wide application prospect. The invention provides a new choice for clinically treating acute pancreatitis, and has a good application prospect.

Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein:or a pharmaceutically acceptable salt thereof.

The invention provides application of a flavin monooxygenase 3 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of medicines. The flavin monooxygenase 3 inhibitor is methimazole or a pharmaceutically acceptable salt, a prodrug or a derivative of methimazole. Experimental results show that after the methimazole is orally taken, the nidus area of animal pancreatitis is obviously reduced, the pathological score is obviously improved, the in-vivo inflammation level is obviously inhibited, and the blood amylase and lipase levels are obviously reduced; the levels of pancreatitis factors and chemotactic factors are reduced, and the oxidative stress index is reduced. In addition, by combining methimazole with the traditional Chinese medicine monomer for inhibiting the trimethylamine oxide level, the curative effect is better. Compared with the prior art, the application has the advantages that the core regulation effect of the trimethylamine oxide in the pathological process of the acute pancreatitis is disclosed for the first time, the limitation of the traditional anti-inflammatory or enzyme replacement therapy is broken through, and the acute pancreatitis is treated by inhibiting the trimethylamine oxide level by inhibiting the flavin monooxygenase 3.

The invention discloses an application of sgRNA targeting PGAM5 in acute pancreatitis as well as a product and a gene therapy drug of the sgRNA. In-vivo experiments prove that the PGAM5-targeted sgRNA can significantly inhibit PGAM5 gene expression, reduce pancreatic tissue inflammatory cell infiltration and reduce serum lipase and amylase levels, thereby blocking generation and development of AP. According to the invention, the targeted knockout of the PGAM5 gene by using the CRISPR-Cas9 system is proposed for the first time, and a new strategy is provided for the gene therapy of AP.

The invention relates to application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine, and belongs to the technical field of medicines. The invention provides an application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine. An antibiotic mixture is used for conducting intragastric administration on a mouse, intestinal bacteria are removed, ILA and STS are subjected to intragastric administration on the mouse, leptofrog and arginine are injected into the abdominal cavity of the mouse for acute pancreatitis modeling, the acute pancreatitis resisting effect of ILA is studied, and the result shows that the amylase concentration in serum of the mouse subjected to intragastric administration of ILA is remarkably reduced; compared with STS, the ILA has the advantages that pancreatic tissue alveolar cell damage and inflammatory infiltration are obviously reduced, inflammatory cytokines in pancreatic tissue and serum are obviously reduced, and compared with STS, the ILA has a better protection effect, so that the ILA has the effect of resisting acute pancreatitis, and a new treatment way is provided for preventing and treating acute pancreatitis.

The invention provides application of L.massiosenegalense and phenyllactic acid generated by the L.massiosenegalense in preparation of a medicine for preventing and treating acute pancreatitis, and belongs to the technical field of biological medicine. The L.massiosenegalense and the phenyllactic acid produced by the L.massiosenegalense can prevent and treat acute pancreatitis, relieve alveolar cell injury and inflammatory cell infiltration caused by acute pancreatitis, and reduce amylase concentration in serum and transcription and expression of inflammatory cytokines in pancreas and serum.

The invention belongs to the technical field of medicine preparation, and particularly relates to curcumin-loaded cerium-based nano-enzyme as well as a preparation method and application thereof. The curcumin-loaded cerium-based nano-enzyme comprises a core carrier, a drug loaded on the core carrier and a shell, the core carrier is a cerium-based metal organic framework; the medicine is curcumin; and the shell is hyaluronic acid. The invention provides the ultra-small nano-enzyme HC (at) CeMOF with strong anti-oxidation and targeting functions, and the data result of the invention shows that the HC (at) CeMOF can be used for treating chronic pancreatitis. Specifically, HC-CeMOF is preferentially gathered at a chronic pancreatitis part by utilizing the inflammation targeting capability of hyaluronic acid, then reactive oxygen species (ROS) at a lesion part is effectively removed and NF-kappa B expression is down-regulated by virtue of the synergistic effect of curcumin and CeMOF, so that a local inflammatory cytokine microenvironment is regulated, and finally pancreatic fibrosis is remarkably improved.

The invention discloses a preparation method and application of a szechwan chinaberry fruit powder extract, and relates to the technical field of Chinese herbal medicines. The method comprises the following steps: respectively crushing and sieving fructus toosendan and rhizoma corydalis decoction pieces, mixing, adding low-concentration ethanol into the mixed powder, and stirring and extracting; sequentially filtering and centrifuging the extracting solution, and collecting supernate; and concentrating the supernate, and performing freeze-drying treatment to obtain the szechwan chinaberry fruit powder extract. Researches find that the extract can significantly reduce amylase and lipase levels in an acute pancreatitis cell model; the general state of a mouse with severe acute pancreatitis is obviously improved, the serum amylase and lipase levels are reduced, the pathological injury of pancreas is relieved, the inflammatory response is inhibited, the infiltration of pancreatic macrophages is inhibited, and the lung injury caused by pancreatitis is effectively improved.

The invention discloses an application of (1S, 2S, 4R)-1-methyl-2, 4-bis (prop-1-ene-2-yl)-1-vinylcyclohexane (alias, beta-elemene) in preparation of a medicine, and the medicine is used for treating or preventing diseases related to acute inflammation, such as acute inflammation, acute inflammation, acute inflammation, acute inflammation and acute inflammation. Comprise acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine, but are not limited to the inducers, and specifically, the inducers can be used for inducing acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine. The medicine can inhibit or improve pathological injury and inflammatory response of lung tissue and pancreatic tissue of acute lung injury and acute pancreatitis.

The invention relates to the technical field of intelligent medical treatment, in particular to an acute pancreatitis specific data fusion method, device and equipment and a medium, and the method comprises the steps: collecting multi-source data of an acute pancreatitis patient; performing single-source coding processing on the multi-source data to obtain multi-source data coding vectors; based on an inflammation waterfall reaction mechanism of pancreatitis, constructing an inflammation stage judgment function, and determining a stage weight coefficient vector of each data in the multi-source data; determining key index mutation weights of the vital sign time sequence data and the laboratory index dynamic data based on mutation identification of the vital sign time sequence data and the laboratory index dynamic data; based on the stage weight coefficient vector and the key index mutation weight, obtaining respective fusion weight of the multi-source data; the fusion vector is obtained based on the respective fusion weight of the multi-source data and the multi-source data coding vector, high-identification-degree feature input is provided for a subsequent severe risk prediction model, and the prediction accuracy and clinical suitability are improved.

The present invention discloses the use of high-density lipoprotein in the preparation of a medicament for preventing or treating acute pancreatitis. The medicament for treating acute pancreatitis provided by the present invention contains high-density lipoprotein, which can effectively reduce the inflammatory response, inflammatory cell infiltration and necrosis of pancreatic acinar cells in patients with acute pancreatitis. The medicament for treating acute pancreatitis provided by the present invention contains high-density lipoprotein, which can selectively accumulate in the pancreatic tissue of patients with acute pancreatitis. High-density lipoprotein not only has the effect of treating acute pancreatitis itself, but also high-density lipoprotein-related nano-biological preparations can be used to carry other anti-inflammatory drugs for targeted treatment of acute pancreatitis, having good clinical application prospects.

The invention relates to the field of biological medicines, and provides application of Amuc1409 protein in prevention and treatment of acute pancreatitis. When the Amuc1409 protein is used for preventing or treating acute pancreatitis, the Amuc1409 protein plays a role through at least one of the following ways: (1) reducing the amylase concentration in serum; (2) relieving acinus cell injury and inflammatory cell infiltration; (3) reducing transcription of inflammatory cytokines in pancreas; and (4) increasing the proportion of regulatory T cells in peripheral blood lymphocytes. The invention discovers and verifies the effect of Ackermann secretory protein Amuc1409 in the aspect of preventing and treating acute pancreatitis for the first time, and the prevention and treatment effect is superior to that of Ackermann membrane protein Amuc1100.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

The invention discloses a YAP signal inhibitor F1113-0335 of a Hippo-YAP signal channel and screening and application of the YAP signal inhibitor F1113-0335, and belongs to the technical field of medical application. According to the technical scheme, the YAP signal inhibitor F1113-0335 of the Hippo-YAP signal channel is provided, the F1113-0335 can inhibit activation of the YAP signal channel and expression of downstream target genes CTGF and CYR61, proliferation activity of tumor cells and YAP signal activation in the tumor cells can be inhibited in a dose-dependent mode, in addition, the in-vivo anti-inflammatory effect of the F1113-0335 is verified in an in-vivo experiment, and the YAP signal inhibitor F1113-0335 can be used for preparing an anti-inflammatory drug. HE staining shows that the F1113-0335 can inhibit the inflammatory injury condition in the tissue, and the F1113-0335 can reverse the mRNA expression level rise of IL-6 and TNF-alpha in the pancreatic tissue of a mouse with acute pancreatitis and up-regulate an anti-inflammatory factor TGF-beta to play an anti-inflammatory role when being used for reversing the mRNA expression level rise of IL-6 and TNF-alpha in the pancreatic tissue of the mouse with acute pancreatitis; qPCR (Quantitative Polymerase Chain Reaction) analysis also shows that the expression of YAP and target genes CTGF and CYR61 thereof is down-regulated by the application of the F1113-0335, the F1113-0335 can inhibit a YAP signal in a mouse acute pancreatitis model induced by rain frog in vivo, and the potential of the F1113 compound as a lead compound of an anti-inflammatory drug is detected on the animal level.

The invention discloses application of butylphthalide in preparation of a medicine for preventing and treating obesity-related acute pancreatitis, and belongs to the technical field of medicines. The invention discloses application of butylphthalide in treatment of obesity-related acute pancreatitis. Pancreatic necrosis, systemic inflammation and distant organ injury caused by obesity-related acute pancreatitis can be remarkably improved. Wherein after intervention of butylphthalide, pathological scores of lung, kidney and pancreas are obviously reduced by 73.08%, 70.00% and 59.26%; the expression level of the pancreatitis marker is obviously reduced and is reduced by 53.80% compared with that of a model group; the expression levels of proinflammatory factors IL-1beta, IL-6 and TNF-alpha in serum are obviously reduced, and are respectively reduced by 69.45%, 78.80% and 67.64% compared with a model group.

The application relates to the field of biological medicine, and particularly relates to application of xanthine nucleoside in preparation of a drug for preventing and treating acute pancreatitis. In the application, it is found that the xanthine nucleoside can significantly improve pancreas inflammation, necrosis and systemic inflammatory response caused by acute pancreatitis, the xanthine nucleoside is used in preparation of the drug for preventing and treating acute pancreatitis, a new strategy is provided for preventing and treating acute pancreatitis, and the application has a good clinical application prospect.

The invention discloses application of phellodendrine in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of biological medicine. The invention discloses a key link in acute pancreatitis pathogenesis that phellodendrine directly acts on neutrophil-mediated excessive inflammatory response and upstream regulation of extracellular trap formation (NETs) for the first time, and reduces the generation of active oxygen by inhibiting the generation of neutrophil extracellular traps of pancreatic tissues, thereby reducing the damage degree of acinus cells. As a small molecule compound, phellodendrine has better tissue permeability and metabolic stability. Compared with a synthetic NETs inhibitor, the natural product has more advantages in the aspect of reducing immunotoxicity. Therefore, the invention proves that the phellodendrine (PHE) realizes the effects of relieving the inflammatory response of the acute pancreatitis and reducing the severity of the acute pancreatitis by targeting immune cells (inhibiting the formation of extracellular traps of neutrophils).

The invention discloses an application of engineered extracellular vesicles targeting IL-6 (interleukin-6) in preparation of a medicine for treating acute pancreatitis. According to the application, an acute pancreatitis model is constructed through intraperitoneal injection of leifrotin and LPS or arginine on C57BL / 6 mice, and after treatment by injection of engineered extracellular vesicles IL6ST-EN144-EVs, serum amylase and lipase levels, IL-6 level, pancreatic tissue pathological score and death rate of the mice are all lower than those of a control group, and pathological changes of acute pancreatitis are obviously improved. The engineered extracellular vesicles IL6ST-EN144-EVs are applicable to preparation of drugs for treating acute pancreatitis, so that targeted treatment of acute pancreatitis inflammation is realized, inflammatory response is remarkably reduced, pancreatic injury is relieved, and the engineered extracellular vesicles IL6ST-EN144-EVs have a good treatment effect.

The application discloses a polypeptide conjugated drug targeting M1 type macrophages and application thereof, and belongs to the technical field of polypeptide conjugated drugs. The polypeptide conjugated drug M1pep-Tasquinimod is composed of a polypeptide targeting M1 type macrophages, a linker and a modified Tasquinimod. The polypeptide conjugated drug can reduce the toxicity of the Tasquinimod, inhibit M1 type polarization of macrophages by targeting proinflammatory M1 type macrophages, and relieve pancreatic tissue lesions of acute pancreatitis mice. The application provides a basis for using the M1pep-Tasquinimod as a novel drug for treating inflammatory diseases.

The application belongs to the technical field of medicine preparation, and particularly relates to a curcumin-loaded cerium-based nanoenzyme as well as a preparation method and application thereof. The curcumin-loaded cerium-based nanoenzyme comprises a core carrier, a drug loaded on the core carrier and a shell; the core carrier is a cerium metal organic framework; the drug is curcumin; and the shell is hyaluronic acid. The application provides a super-small nanoenzyme HC@CeMOF with strong antioxidant and targeting functions, and data results of the application show that the HC@CeMOF can be used for treating chronic pancreatitis. Specifically, the HC@CeMOF can be used for treating chronic pancreatitis by utilizing the inflammation targeting ability of hyaluronic acid, so that the HC@CeMOF is preferentially gathered at a chronic pancreatitis inflammation site, then through the synergistic effect of curcumin and CeMOF, active oxygen (ROS) at the lesion site is effectively removed, and the expression of NF-kappa B is down-regulated, so as to regulate the local inflammatory cytokine microenvironment, and finally significantly improve the pancreas fibrosis.

The invention relates to a fusion protein containing selenomethionine and application of the fusion protein in treating acute pancreatitis, and belongs to the technical field of biological medicines. The fusion protein is prepared from a TAT-14-PTD-p65 fusion protein and organic selenium (selected from selenomethionine) through an in-vivo biochelation method, the fusion protein adopts an Nrf2 activation-NF-kappa B inhibition-selenium donor three-in-one design, and comprises an Nrf2 activation element (TAT-14 peptide), an NF-kappa B inhibition element (PTD-p65-P1) and a selenium donor element (selenomethionine) which are connected through a (Gly4Ser) 2 connecting peptide so as to avoid spatial interference. Experiments show that the fusion protein and the selenium chelate thereof can significantly reduce serum lipase and amylase levels of C57 mice with acute pancreatitis, inhibit inflammatory response and oxidative stress and relieve pancreatic tissue damage by inhibiting pancreatic tissue NF-kB inflammatory pathway activation and up-regulating pancreatic Nrf2 / HO-1 antioxidant pathway, and the selenium chelate has a better effect.

The invention relates to the technical field of biological pharmacy, and particularly discloses application of protostemonine or pharmaceutical salt thereof in preparation of a medicine for preventing or treating acute pancreatitis. The establishment of an acute pancreatitis animal model induced by combination of rain frog element and LPS proves that protostemonine can significantly reduce the activity of model mouse serum amylase and lipase, alleviate pancreatic tissue pathological damage, inhibit the activity of pancreatic tissue myeloperoxidase (MPO) and mRNA expression of inflammatory factors IL-1beta, IL-6 and TNF-alpha, and inhibit pancreatic tissue myeloperoxidase (MPO). Therefore, local inflammation and tissue damage of the pancreas are effectively relieved. An in-vitro cell experiment further verifies the biological activity of the compound. The invention provides a new drug choice for clinical treatment of acute pancreatitis, and has a good development prospect. The medicine can be prepared into various dosage forms such as injections, tablets, capsules and the like, and can be combined with other anti-inflammatory medicines for use.